About This Project
An estimated 6 – 7 million people in Latin America and 300,000 U.S. citizens are infected with the protozoan parasite Trypanosoma cruzi that results in Chagas’ disease, a neglected tropical disease (NTD). Principally spread by the kissing bug (cover image), there exists an urgent need for development of new therapeutics to replace the outdated clinically used drugs, benznidazole and nifurtimox. Our research focuses on the discovery of novel antichagasic compounds for improved medicine.
Recent Lab Notes From This Project
Browse Other Projects on Experiment
Personalized Cancer and Viral Therapy: Clostridium-based Cell Delivery System coupled to CRISPR/Cas9 Nanotherapeutic
One of the fundamental weaknesses in cancer treatment or any therapy based at the cellular level is entering...